Dr Zev Wainberg speaks to ecancer about the phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic oesophageal cancer. Initially, he explains the background of the study.

He then, discusses the methodology and results of this study.

Dr Wainberg concludes, saying that tiragolumab combined with atezolizumab was well-tolerated with an acceptable safety profile, and showed preliminary anti-tumour activity in heavily pretreated patients with metastatic oesophageal cancers not previously treated with cancer immunotherapy.